What analyte is least beneficial when determining if a patient has had an Acute Myocardial Infarction (AMI)?

Prepare for the CAMLPR Specimen Collection Competency Test. Practice with diverse question sets including multiple-choice and flashcards. Each question includes hints and explanations to help you become proficient before the exam.

When assessing whether a patient has had an Acute Myocardial Infarction, we rely on biomarkers that specifically reflect heart muscle injury and behave predictably over time. Troponin is the gold standard because it is highly sensitive and specific to cardiac tissue and remains elevated for days, making it easy to detect an infarct even if the event occurred earlier. CK-MB is still useful as a myocardial marker, rising after troponin and helping in certain scenarios such as identifying reinfarction, but it is not as specific as troponin. Myoglobin rises very early after injury, which is helpful for early detection, but it lacks specificity since it is found in skeletal muscle and other tissues as well. Lactate dehydrogenase, on the other hand, is present in many tissues beyond the heart and its elevations are less specific and slower to rise and fall, making it the least useful for confirming an AMI. That’s why lactate dehydrogenase is considered the least beneficial among these markers for diagnosing an acute myocardial infarction.